Back to results
US 2024/0255496 A1Published application
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
AssigneeHorizon Therapeutics USA, Inc.
InventorsTheresa ROSARIO-JANSEN, David Erick WRIGHT
Life of this patent
Estimating the term…
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Claims12
A method of treating gout in a patient, the method comprising:
- a. administering to the patient a PEGylated uricase protein every 4 weeks;
- b. measuring the serum uric acid (SUA) level of the patient after each said administration;
- and
- c. discontinuing administration of the PEGylated uricase if the patient's SUA level is above 6 mg/dl.
1 more element
Dependencies are inferred from the claim text.